肥厚型心肌病治疗新进展

黄纬凌; 杨俊

doi:10.13201/j.issn.1001-1439.2016.08.003

肥厚型心肌病治疗新进展

黄纬凌,
杨俊^,

- 三峡大学心血管病研究所三峡大学第一临床医学院心内科(湖北宜昌, 443003)
基金项目:
国家自然科学基金项目(No:81170133

81200088

81470387)

详细信息

通讯作者: 杨俊,E-mail:yangjun@ctgu.edu.cn

中图分类号: R542.2

收稿日期: 2016-04-25

Progress of hypertrophic cardiomyopathy therapy

HUANG Wei-ling,
YANG Jun^,

- Department of Cardiology, First Clinical College of Three Gorges University, Yichang, Hubei, 443003, China

More Information

Corresponding author: YANG Jun, E-mail: yangjun@ctgu.edu.cn

Received Date: 25 April 2016

摘要

摘要: 肥厚型心肌病(Hypertrophic cardiomyopathy,HCM)的传统治疗主要包括口服药物治疗和手术治疗,由于临床期的患者已经发生心室重构,所以口服药物治疗主要在HCM的临床前期有较好疗效。本文主要对HCM的治疗,及其常见合并症的处理方法的最新研究进展进行综述。
- 肥厚型心肌病 /
- 心律转复除颤器 /
- 心房颤动 /
- 慢性阻塞性肺疾病
Abstract: Traditional treatment of hypertrophic cardiomyopathy(HCM)mainly includes oral drug therapy and surgery.Oral drug therapy has better curative effect mainly in preclinical HCM,because the patients had already developed ventricular remodeling in clinical stage.This paper reviews the latest research progress in the treatment of HCM and its common complications.
- hypertrophic cardiomyopathy /
- implantable cardioverter defibrillator /
- artrial fibrillation /
- chronic obstructive pulmonary disease

HTML全文

参考文献(19)

[1]	AKITA K,MAEKAWA Y,TSURUTA H,et al."Moving left ventricular obstruction"due to stress cardiomyopathy in apatient with hypertrophic obstructive cardiomyopathy treated withpercutaneous transluminal septal myocardial ablation[J],Int J Cardiol,2015,145:194-195.
[2]	MARIANA J.Experimental therapies in hypertrophic cardiom-yopathy[J].J Cardiovasc Transl Res,2009,2:483-492.
[3]	ARAUJO A Q,ARTEAGA E,IANNI B M.Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy[J].Am J Cardiol,2005,96:1563-1567.
[4]	HOUSTON B,STEVENS G.Hypertrophic cardiomyopathy:a review[J].Clin Med Insights:Cardiol,2014,8:53-65.
[5]	LOMBARDI R,RODRIGUEZ G,CHENS N,et al.Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms[J].Circulation,2009,119:1398-1407.
[6]	VAKROU S,ABRAHAMM R.Hypertrophic cardiomyopathy:a heart in need of an energy bar?[J].Front Physiol,2014,19:309-410.
[7]	ALVESM L,DIASF A,GAFFINR D,et al.Desensitization of myofilaments to Ca 2+as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins[J].Circ Cardiovasc Gene,2014,7:132-143.
[8]	LIEBREGTS M,VRIESENDORPP A,MAHMOODIB K,et al.A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy[J].JACC Heart Fail,2015,11:896-905.
[9]	MORAVSKY G,BRUCHAL-GARBICZ B,JAMORSKI M,et al.Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy[J].J Am Soc Echocardiog,2013,26:801-920.
[10]	OMMENS R,MARONB J,OLIVOTTO I,et al.Long-term effects of surgical septalmyectomy on survival in patients with obstructive hypertrophic cardiomyopathy[J].JACC,2005,46:470-476.
[11]	FABER L.Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy:from experiment to standard of care[J].Adv Med,2014,6:1-14.
[12]	EFTHIMIADISG K,PAGOURELIASE D,GOSSIOS T,et al.Hypertrophic cardiomyopathy in 2013:Current speculations and future perspectives[J].World J Cardiol,2014,6:26-37.
[13]	GARCIA-PAVIA P,COMÍN-COLET J,BARRIALES-VILLA R,et al.Comments on the 2014 esc guidelines on the diagnosis and management of hypertrophic cardiomyopathy.A critical view from the perspective of spanish cardiology[J].Rev Esp Cardiol,2015,68:4-9.
[14]	BETOCCHI S,LOSI M A,PISCIONE F,et al.Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstructionand on diastolic function[J].Am J Cardiol,1996,77:498-502.
[15]	SINIORAKIS E,ARVANITAKIS S,PAVLOUROS T,et al.Chronic obstructive pulmonary disease and hypertrophic obstructive cardiomyopathy:Two antagonistic obstructions[J].Int J Cardiol,2014,176,e129-e130.
[16]	YASHIRO B,MINAMI Y,TERAJIMA Y,et al.Prognostic difference between paroxysmal and nonparoxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy[J].J Cardiol,2014,63:391-460.
[17]	BASSIOUNY M,LINDSAYB D,LEVER H,et al.Outcomes of nonpharma-cologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy[J].Heart Rhythm,2015,12:1405-1716.
[18]	FERNANDO M,UXTONA E,JOSEPHSONM E,et al.Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy:long-term outcomes and clinical predictors[J].JACC,2015,65:1385-1496.
[19]	ASHIKHMINAA E,FARBERBM K,MIZUGUCHIBK A,et al.Parturients with hypertrophic cardiomyopathy:case series and review of pregnancy outcomes and anesthetic management of labor and delivery[J].Int J Obstet Anesth,2015,24:293-400.